Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Pitolisant: Difference between revisions

From Pharmacopedia
[pending revision][pending revision]
Recategorize: Stimulants -> Psychostimulants
Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.
Line 13: Line 13:
| bioavailability = Not formally established; oral once-daily adequate
| bioavailability = Not formally established; oral once-daily adequate
| pregnancy      = Limited data; pitolisant may reduce hormonal contraceptive efficacy
| pregnancy      = Limited data; pitolisant may reduce hormonal contraceptive efficacy
| legal          = Rx '''not a controlled substance''' (unique among wake-promoting agents)
| legal          = Rx, '''not a controlled substance''' (unique among wake-promoting agents)
| intro          = '''Pitolisant''' (brand name Wakix) is a selective histamine H3 receptor inverse agonist FDA-approved in August 2019 for excessive daytime sleepiness and cataplexy in narcolepsy. Notable for being '''not a controlled substance''' unique among approved wake-promoting medicines, all of which have abuse potential and DEA scheduling (modafinil IV, methylphenidate II, amphetamine II, solriamfetol IV, sodium oxybate III).
| intro          = '''Pitolisant''' (brand name Wakix) is a selective histamine H3 receptor inverse agonist FDA-approved in August 2019 for excessive daytime sleepiness and cataplexy in narcolepsy. Notable for being '''not a controlled substance''', unique among approved wake-promoting medicines, all of which have abuse potential and DEA scheduling (modafinil IV, methylphenidate II, amphetamine II, solriamfetol IV, sodium oxybate III).


Mechanism: H3 autoreceptors on histamine neurons in the tuberomammillary nucleus normally inhibit histamine release. Pitolisant blocks (or inverse-agonizes) these autoreceptors, disinhibiting histamine release and promoting wakefulness. Downstream effects on acetylcholine, norepinephrine, and dopamine pathways may also contribute. Slow titration required.
Mechanism: H3 autoreceptors on histamine neurons in the tuberomammillary nucleus normally inhibit histamine release. Pitolisant blocks (or inverse-agonizes) these autoreceptors, disinhibiting histamine release and promoting wakefulness. Downstream effects on acetylcholine, norepinephrine, and dopamine pathways may also contribute. Slow titration required.